United States Clinical Chemistry Market Outlook to 2024

Published : Nov-2017

No. of Pages : 305

order by fax Inquire before Buying request discount

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 2
1.2 List of Figures 5
2 Introduction 6
2.1 What Is This Report About? 6
2.2 Clinical Chemistry Market Segmentation 6
2.3 Definitions of Markets Covered in the Report 8
3 Clinical Chemistry Market, United States 13
3.1 Clinical Chemistry Market, United States, Revenue ($m), 2010-2017 13
3.2 Clinical Chemistry Market, United States, Revenue ($m), 2017-2024 15
3.3 Clinical Chemistry Market, United States, Volume (Units), 2010-2017 49
3.4 Clinical Chemistry Market, United States, Volume (Units), 2017-2024 51
3.5 Clinical Chemistry Market, United States, Average Price ($), 2010-2024 77
3.6 Clinical Chemistry Market, United States, Distribution Share by Revenue ($m), 2017 81
3.7 Clinical Chemistry Market, United States, Company Share by Revenue ($m), 2017 82
4 Overview of Key Companies in United States, Clinical Chemistry Market 84
4.1 F. Hoffmann-La Roche Ltd 84
4.2 Abbott Laboratories 84
4.3 Ortho-Clinical Diagnostics Inc 84
4.4 Siemens Healthcare GmbH 84
4.5 Beckman Coulter Inc 85
4.6 Meridian Bioscience Inc 85
4.7 Thermo Fisher Scientific Inc 85
4.8 Mindray Medical International Ltd 86
4.9 Randox Laboratories Ltd 86
4.10 Hitachi Ltd 86
4.11 Orion Diagnostica Oy 86
5 Clinical Chemistry Market Pipeline Products 88
6 Financial Deals Landscape 89
6.1 Acquisition 89
6.2 Debt Offerings 90
6.3 Equity Offerings 134
6.4 Private Equity 142
6.5 Venture Financing 143
7 Recent Developments 148
7.1 Corporate Communications 148
7.2 Financial Announcements 175
7.3 Government and Public Interest 271
7.4 Legal And Regulatory 272
7.5 Other Significant Developments 276
7.6 Product News 281
7.7 Research And Development 289
7.8 Strategy And Business Planning 290
8 Appendix 293
8.1 Research Methodology 294
8.2 GlobalData Consulting 298
8.3 Contact Us 299
8.4 Disclaimer 299

1.1 List of Tables
Table 1: Clinical Chemistry Market, United States, Revenue ($m), USD Constant, Historic, 2010-2017 20
Table 2: Clinical Chemistry Market, United States, Revenue ($m), USD Constant, Forecast, 2017-2024 22
Table 3: Blood Test Strips - Rapid Tests & POC Market, United States, Revenue ($m), USD Constant, Historic, 2010-2017 24
Table 4: Clinical Chemistry Analyzers Market, United States, Revenue ($m), USD Constant, Historic, 2010-2017 26
Table 5: Enzyme Chemistry Reagents Market, United States, Revenue ($m), USD Constant, Historic, 2010-2017 28
Table 6: Feces Tests - Rapid Tests & POC Market, United States, Revenue ($m), USD Constant, Historic, 2010-2017 30
Table 7: Substrates Market, United States, Revenue ($m), USD Constant, Historic, 2010-2017 32
Table 8: Therapeutic Drug Monitoring Market, United States, Revenue ($m), USD Constant, Historic, 2010-2017 34
Table 9: Urine Analysis Market, United States, Revenue ($m), USD Constant, Historic, 2010-2017 36
Table 10: Urine Testing - Rapid Tests & POC Market, United States, Revenue ($m), USD Constant, Historic, 2010-2017 38
Table 11: Blood Test Strips - Rapid Tests & POC Market, United States, Revenue ($m), USD Constant, Forecast, 2017-2024 40
Table 12: Clinical Chemistry Analyzers Market, United States, Revenue ($m), USD Constant, Forecast, 2017-2024 42
Table 13: Enzyme Chemistry Reagents Market, United States, Revenue ($m), USD Constant, Forecast, 2017-2024 44
Table 14: Feces Tests - Rapid Tests & POC Market, United States, Revenue ($m), USD Constant, Forecast, 2017-2024 46
Table 15: Substrates Market, United States, Revenue ($m), USD Constant, Forecast, 2017-2024 48
Table 16: Therapeutic Drug Monitoring Market, United States, Revenue ($m), USD Constant, Forecast, 2017-2024 50
Table 17: Urine Analysis Market, United States, Revenue ($m), USD Constant, Forecast, 2017-2024 52
Table 18: Urine Testing - Rapid Tests & POC Market, United States, Revenue ($m), USD Constant, Forecast, 2017-2024 54
Table 19: Clinical Chemistry Market, United States, Volume (Units), Historic, 2010-2017 56
Table 20: Clinical Chemistry Market, United States, Volume (Units), Forecast, 2017-2024 58
Table 21: Blood Test Strips - Rapid Tests & POC Market, United States, Volume (Units), Historic, 2010-2017 60
Table 22: Clinical Chemistry Analyzers Market, United States, Volume (Units), Historic, 2010-2017 62
Table 23: Enzyme Chemistry Reagents Market, United States, Volume (Units), Historic, 2010-2017 64
Table 24: Feces Tests - Rapid Tests & POC Market, United States, Volume (Units), Historic, 2010-2017 66
Table 25: Substrates Market, United States, Volume (Units), Historic, 2010-2017 68
Table 26: Urine Testing - Rapid Tests & POC Market, United States, Volume (Units), Historic, 2010-2017 70
Table 27: Blood Test Strips - Rapid Tests & POC Market, United States, Volume (Units), Forecast, 2017-2024 72
Table 28: Clinical Chemistry Analyzers Market, United States, Volume (Units), Forecast, 2017-2024 74
Table 29: Enzyme Chemistry Reagents Market, United States, Volume (Units), Forecast, 2017-2024 76
Table 30: Feces Tests - Rapid Tests & POC Market, United States, Volume (Units), Forecast, 2017-2024 78
Table 31: Substrates Market, United States, Volume (Units), Forecast, 2017-2024 80
Table 32: Urine Testing - Rapid Tests & POC Market, United States, Volume (Units), Forecast, 2017-2024 82
Table 33: Clinical Chemistry Market, United States, Average Price ($) Historic, 2010-2017 83
Table 34: Clinical Chemistry Market, United States, Average Price ($), Forecast, 2017-2024 85
Table 35: Clinical Chemistry Market, United States, Distribution Share by Revenue ($m), USD Constant, 2016-2017 87
Table 36: Clinical Chemistry Market, United States, Company Share by Revenue ($m), USD Constant, 2017 89
Table 37: Clinical Chemistry Market Pipeline Products 94
Table 38: BioIVT Acquires Qualyst Transporter Solutions 95
Table 39: Hologic Raises USD350 Million in Private Placement of 4.375% Notes Due 2025 96
Table 40: Rosetta Genomics Raises USD2 Million in Private Placement of Debentures and Warrants 97
Table 41: Thermo Fisher Scientific Raises USD750 Million in Public Offering of 4.1% Notes Due 2047 98
Table 42: Thermo Fisher Scientific Raises USD750 Million in Public Offering of 3.2% Notes Due 2027 100
Table 43: BioMarin Pharma Completes Underwriters Exercise of Over-Allotment Option of 0.599% Notes Due 2024 for USD45 Million 102
Table 44: Thermo Fisher Scientific Raises USD573.3 Million in Public Offering of Floating Rate Notes Due 2019 103
Table 45: Thermo Fisher Scientific Raises USD802.6 Million in Public Offering of 1.4% Notes Due 2026 105
Table 46: Thermo Fisher Scientific Raises USD802.6 Million in Public Offering of 1.95% Notes Due 2029 107
Table 47: Thermo Fisher Scientific Raises USD802.6 Million in Public Offering of 2.875% Notes Due 2037 109
Table 48: Becton, Dickinson to Raise USD1 Billion in Public Offering of 2.404% Notes Due 2020 112
Table 49: Becton, Dickinson to Raise USD1.8 Billion in Public Offering of 2.894% Notes Due 2022 113
Table 50: Becton, Dickinson to Raise USD500 Million in Public Offering of Floating Rate Notes Due 2022 114
Table 51: Becton, Dickinson to Raise USD1.75 Billion in Public Offering of 3.363% Notes Due 2024 115
Table 52: Becton, Dickinson to Raise USD2.4 Billion in Public Offering of 3.7% Notes Due 2027 116
Table 53: Becton, Dickinson to Raise USD1.5 Billion in Public Offering of 4.669% Notes Due 2047 117
Table 54: Becton, Dickinson to Raise USD788 Million in Public Offering of 0.368% Notes Due 2019 118
Table 55: AMAG Pharma Prices Public Offering of 3.25% Notes Due 2022 for USD300 Million 119
Table 56: Transgenomic Raises USD1.2 Million in Private Placement 121
Table 57: Thermo Fisher Scientific Prices Public Offering of 1.45% Notes Due 2027 for USD530 Million 122
Table 58: Becton Dickinson Prices Public Offering of 1% Notes Due 2022 for USD500 Million 124
Table 59: Becton Dickinson Prices Public Offering of 1.9% Notes Due 2026 for USD500 Million 126
Table 60: Abbott Labs Raises USD2.85 Billion in Public Offering of 2.35% Notes due 2019 128
Table 61: Abbott Labs Raises USD2.85 Billion in Public Offering of 2.9% Notes due 2021 130
Table 62: Abbott Labs Raises USD1.5 Billion in Public Offering of 3.4% Notes Due 2023 132
Table 63: Abbott Labs Raises USD3 Billion in Public Offering of 3.75% Notes due 2026 134
Table 64: Abbott Labs Raises USD1.65 Billion in Public Offering of 4.75% Notes due 2036 136
Table 65: Abbott Labs Raises USD3.25 Billion in Public Offering of 4.9% Notes due 2046 138
Table 66: Thermo Fisher Scientific Prices Public Offering of Shares for USD1.5 Billion 140
Table 67: Chembio Diagnostics to Raise up to USD21.2 Million in Public Offering of Shares 142
Table 68: Becton Dickinson Raises USD2.47 Billion in Public Offering of Shares 143
Table 69: Becton Dickinson Raises USD2.47 Billion in Public Offering of Depositary Shares 145
Table 70: International Isotopes Raises USD3.4 Million in Private Placement of Series C Preferred Stock 147
Table 71: Essex Woodlands Management Invests Additional USD15 Million in Metabolon 148
Table 72: SenGenix Raises USD6.3 Million in Financing 149
Table 73: CytoVas Raises USD0.1 Million in Venture Financing 150
Table 74: Ativa Medical Raises USD9.5 Million in Venture Financing 151
Table 75: Akonni Biosystems Raises USD4 Million in Venture Financing 152
Table 76: Ceres Nanosciences Raises USD3 Million in First Tranche of Series A Financing 153
Table 77: Total Number of Primary Research Participants, In Vitro Diagnostics Market, by Country 302

1.2 List of Figures
Figure 1: Clinical Chemistry Market, United States, Revenue ($m), USD Constant, Historic, 2010-2017 19
Figure 2: Clinical Chemistry Market, United States, Revenue ($m), USD Constant, Forecast, 2017-2024 21
Figure 3: Blood Test Strips - Rapid Tests & POC Market, United States, Revenue ($m), USD Constant, Historic, 2010-2017 23
Figure 4: Clinical Chemistry Analyzers Market, United States, Revenue ($m), USD Constant, Historic, 2010-2017 25
Figure 5: Enzyme Chemistry Reagents Market, United States, Revenue ($m), USD Constant, Historic, 2010-2017 27
Figure 6: Feces Tests - Rapid Tests & POC Market, United States, Revenue ($m), USD Constant, Historic, 2010-2017 29
Figure 7: Substrates Market, United States, Revenue ($m), USD Constant, Historic, 2010-2017 31
Figure 8: Therapeutic Drug Monitoring Market, United States, Revenue ($m), USD Constant, Historic, 2010-2017 33
Figure 9: Urine Analysis Market, United States, Revenue ($m), USD Constant, Historic, 2010-2017 35
Figure 10: Urine Testing - Rapid Tests & POC Market, United States, Revenue ($m), USD Constant, Historic, 2010-2017 37
Figure 11: Blood Test Strips - Rapid Tests & POC Market, United States, Revenue ($m), USD Constant, Forecast, 2017-2024 39
Figure 12: Clinical Chemistry Analyzers Market, United States, Revenue ($m), USD Constant, Forecast, 2017-2024 41
Figure 13: Enzyme Chemistry Reagents Market, United States, Revenue ($m), USD Constant, Forecast, 2017-2024 43
Figure 14: Feces Tests - Rapid Tests & POC Market, United States, Revenue ($m), USD Constant, Forecast, 2017-2024 45
Figure 15: Substrates Market, United States, Revenue ($m), USD Constant, Forecast, 2017-2024 47
Figure 16: Therapeutic Drug Monitoring Market, United States, Revenue ($m), USD Constant, Forecast, 2017-2024 49
Figure 17: Urine Analysis Market, United States, Revenue ($m), USD Constant, Forecast, 2017-2024 51
Figure 18: Urine Testing - Rapid Tests & POC Market, United States, Revenue ($m), USD Constant, Forecast, 2017-2024 53
Figure 19: Clinical Chemistry Market, United States, Volume (Units), Historic, 2010-2017 55
Figure 20: Clinical Chemistry Market, United States, Volume (Units), Forecast, 2017-2024 57
Figure 21: Blood Test Strips - Rapid Tests & POC Market, United States, Volume (Units), Historic, 2010-2017 59
Figure 22: Clinical Chemistry Analyzers Market, United States, Volume (Units), Historic, 2010-2017 61
Figure 23: Enzyme Chemistry Reagents Market, United States, Volume (Units), Historic, 2010-2017 63
Figure 24: Feces Tests - Rapid Tests & POC Market, United States, Volume (Units), Historic, 2010-2017 65
Figure 25: Substrates Market, United States, Volume (Units), Historic, 2010-2017 67
Figure 26: Urine Testing - Rapid Tests & POC Market, United States, Volume (Units), Historic, 2010-2017 69
Figure 27: Blood Test Strips - Rapid Tests & POC Market, United States, Volume (Units), Forecast, 2017-2024 71
Figure 28: Clinical Chemistry Analyzers Market, United States, Volume (Units), Forecast, 2017-2024 73
Figure 29: Enzyme Chemistry Reagents Market, United States, Volume (Units), Forecast, 2017-2024 75
Figure 30: Feces Tests - Rapid Tests & POC Market, United States, Volume (Units), Forecast, 2017-2024 77
Figure 31: Substrates Market, United States, Volume (Units), Forecast, 2017-2024 79
Figure 32: Urine Testing - Rapid Tests & POC Market, United States, Volume (Units), Forecast, 2017-2024 81
Figure 33: Clinical Chemistry Market, United States, Company Share (%) 2017 88

Filed in: In Vitro Diagnostic, Medical Device

Publisher : GlobalData

Name:
Email:
Phone:
Subject:
Comments:

More Reports

Title	Price	Buy Now
In Vitro Fertilization /IVF Market by Product (Micromanipulators, Incubators, Cabinets, Imaging System, Laser System, Reagents & Accessories), Type (Conventional IVF, IVF with ICSI), End User (Fertility Clinics, Hospitals, Cryobanks) – Global Forecast to 2026 “The global in vitro fertilization market size is projected to reach USD 987 million by 2026 from USD 638 million in 2021, at a CAGR of 9.1 % during the forecast period” The global in vitro fertilization market is projected to reach USD 987 million by 2026 from USD 638 million in 2021, at a CAGR of 9.1% from 2021 to 2026. The key factors fueling the growth of this market include an increase in the median age of first-time mothers, declining fertility rates, rising male infertility, rise in obesity rate and growing consumption of alcohol, and growing awareness about the availability of treatment options. However, the high cost and low success rate of IVF treatment and restrictive regulations and ethical concerns are expected to restrict the growth of the IVF market to a certain e......	$4950
Assisted Reproductive Technology Devices (General Surgery) – Global Market Analysis and Forecast Model (COVID-19 market impact) Assisted Reproductive Technology Devices (General Surgery) - Global Market Analysis and Forecast Model (COVID-19 market impact) Summary Assisted Reproductive Technology Devices (General Surgery) - Global Market Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within General Surgery therapeutic area. The model discusses in detail the impact of COVID-19 on Assisted Reproductive Technology Devices market for the year 2020 and beyond. Assisted Reproductive Technology (ART) refers to reproductive health procedures that treat infertile women to achieve pregnancy. For decades now across much of the developed world, several techniques of ART have been in use with varying pregnancy success rates. These techniques primarily include, but are no......	$7500
Multiparameter CT/NG NAAT Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model (COVID-19 Market Impact) Multiparameter CT/NG NAAT Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 Market Impact) Summary Multiparameter CT/NG NAAT Tests (In Vitro Diagnostics) - Global Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. The model discusses in detail the impact of COVID-19 on Multiparameter CT/NG NAAT Tests market for the year 2020 and beyond. Chlamydia is a common sexually transmissible disease, caused by the bacteria Chlamydia Trachomatis. In women, Chlamydia Trachomatis infections are often asymptomatic, however, if left untreated they can cause pelvic inflammatory disease (PID), which in turn can lead to additional complications such as infertility, ectopic preg......	$7500
Hemophilia A and B – Global Drug Forecast and Market Analysis to 2028 Hemophilia A and B - Global Drug Forecast and Market Analysis to 2028 Summary Hemophilia A and B are rare, genetic, X-linked deficiencies in the blood clotting factors VIII (FVIII) and IX (FIX), respectively. Patients can be categorized as mild, moderate or severe depending on the percentage of circulating FVIII or FIX in their blood. Patients can be treated either on-demand or prophylactically using plasma-derived or recombinant replacement factors, the current standard of care. Although these therapies are effective, they are associated with a great treatment burden. There is a significant unmet need for new therapies that can reduce the great treatment burden associated with intravenous administration, the frequency of prophylactic infusions, and the risk of developing neutralizing a......	$10995
Human Immunodeficiency Virus (HIV) Tests (In Vitro Diagnostic) – Global Market Analysis and Forecast Model Human Immunodeficiency Virus (HIV) Tests (In Vitro Diagnostic) - Global Market Analysis and Forecast Model Summary Human Immunodeficiency Virus (HIV) Tests (In Vitro Diagnostic) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. Human Immunodeficiency Virus (HIV) has become one of the world's most serious health issues affecting approximately 36.9 million people. The epidemiology of HIV infections varies from one geographical region to another. Sources indicate that in many countries, incidence rates for HIV have stabilized due to the campaigns that provide condoms, pre-exposure prophylaxis, sterile needles, syringes, antiretroviral therapy (ART), and prevention of mother-to-child transmission interv......	$7500
Chlamydia Trachomatis Tests (In Vitro Diagnostic) – Global Market Analysis and Forecast Model Chlamydia Trachomatis Tests (In Vitro Diagnostic) - Global Market Analysis and Forecast Model Summary Chlamydia Trachomatis Tests (In Vitro Diagnostic) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. Chlamydia is a common sexually transmissible disease, caused by the bacteria Chlamydia trachomatis. Patient access to Chlamydia screening, and thus the number of reported cases, varies substantially between countries. In some countries annual screening is recommended for specific patient groups deemed to be at higher risk of contracting the disease, such as sexually active females younger than 25 years. Additionally, screening of pregnant women for Chlamydia Trachomatis infections is currently recomme......	$7500
EGFR Tests (In Vitro Diagnostic) – Global Market Analysis and Forecast Model EGFR Tests (In Vitro Diagnostic) - Global Market Analysis and Forecast Model Summary EGFR Tests (In Vitro Diagnostic) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. Globally, lung cancer is the second most common cancer in men and the third most common cancer in women. There are two main types of lung cancer; small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), with NSCLC accounting for approximately 80-90% of all lung cancer cases. The 5-year survival rate for patients with stage IV disease is less than 5% as majority of patients present with the advanced or metastatic disease at diagnosis. EGFR is a member of the receptor tyrosine kinase family and a major factor in regulating ......	$7500
Human Papilloma Virus (HPV) Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model Human Papilloma Virus (HPV) Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model Summary Human Papilloma Virus (HPV) Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. Cervical cancer screening has traditionally been based on cervical cytology. In recent years however, many countries have incorporated Human Papilloma Virus (HPV) tests into their cervical cancer and pre-cancer screening programs. Cytology based screening programs require a well-established healthcare infrastructure for processing and interpretation of samples. It is hoped that HPV screening methods may enable better prevention of these disease, these devices are also highly sensitive an......	$7500
Cytomegalovirus (CMV) Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model "Cytomegalovirus (CMV) Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model Summary Cytomegalovirus (CMV) Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. Cytomegalovirus (CMV) represents the most common congenital, viral infection in the developed world and awareness of this disease is increasing. Few countries have official guidelines in place for CMV screening but in general testing tends to be performed for sperm donations, immunocompromised cases, and pregnant women. Diagnosis of CMV infections is complex as symptoms are often non-specific and mimic mononucleosis or the flu. Approximately 21-25% of primary CMV infections are symptomatic ......	$7500
Prenatal Screening (In Vitro Diagnostics) – Global Market Analysis and Forecast Model Prenatal Screening (In Vitro Diagnostics) - Global Market Analysis and Forecast Model Summary Prenatal Screening (In Vitro Diagnostics) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. Prenatal Screening is now routinely used in developed countries for early detection of fetal abnormalities. Various biochemical analytes are measured during the first or second trimester including free-beta human chorionic gonadotropin (hCG), total hCG, pregnancy associated plasma protein-A (PAPP-A), Alpha-fetoprotein (AFP), unconjugated estriol (uE3), and Inhibin A. These markers are used to screen for Down syndrome (Trisomy 21) as well as Edwards syndrome (Trisomy 18) and ectopic pregnancy. Additionally, maternal s......	$7500

United States Clinical Chemistry Market Outlook to 2024

Benefits of Sandler Research

User License for Reports

Reach Us

Contact Us

Knowledge Store

Email Subscription

our Feed Reader

In Vitro Fertilization /IVF Market by Product (Micromanipulators, Incubators, Cabinets, Imaging System, Laser System, Reagents & Accessories), Type (Conventional IVF, IVF with ICSI), End User (Fertility Clinics, Hospitals, Cryobanks) – Global Forecast to 2026

Assisted Reproductive Technology Devices (General Surgery) – Global Market Analysis and Forecast Model (COVID-19 market impact)

Multiparameter CT/NG NAAT Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model (COVID-19 Market Impact)

Hemophilia A and B – Global Drug Forecast and Market Analysis to 2028

Human Immunodeficiency Virus (HIV) Tests (In Vitro Diagnostic) – Global Market Analysis and Forecast Model

Chlamydia Trachomatis Tests (In Vitro Diagnostic) – Global Market Analysis and Forecast Model

EGFR Tests (In Vitro Diagnostic) – Global Market Analysis and Forecast Model

Human Papilloma Virus (HPV) Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model

Cytomegalovirus (CMV) Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model

Prenatal Screening (In Vitro Diagnostics) – Global Market Analysis and Forecast Model